006280.KS - GC Biopharma Corp.

KSE - KSE Delayed price. Currency in KRW

GC Biopharma Corp.

107, Ihyeon-ro 30beon-gil
South Korea
82 3 1260 9300

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Il-Sup Huh Ph.D.Chairman & CEON/AN/A1954
Mr. Eun-Cheol HurPres & DirectorN/AN/A1972
Mr. Min-Taek LeeSr. Managing Director of SalesN/AN/A1963
Mr. Young Sup HuhExec. VPN/AN/A1941
Mr. In-Jae LeeSr. MD & DirectorN/AN/A1963
Mr. Byeong-Hwa KimVP & DirectorN/AN/A1958
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.


GC Biopharma Corp., a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis. In addition, the company provides over the counter drugs. It also exports its products to approximately 50 countries. The company has a licensing and collaboration agreement with Tottori University for development of GM1 gangliosidosis chaperone therapy. GC Biopharma Corp. was founded in 1967 and is headquartered in Yongin-si, South Korea. GC Biopharma Corp. is a subsidiary of Green Cross Holdings Corporation.

Corporate governance

GC Biopharma Corp.’s ISS governance QualityScore as of 1 June 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.